Cover Image
Market Research Report

US Procedure Numbers for Orthopedic Biomaterials 2017 - MedPro

Published by iData Research Inc. Product code 454942
Published Content info 459 Pages
Delivery time: 1-2 business days
Price
Back to Top
US Procedure Numbers for Orthopedic Biomaterials 2017 - MedPro
Published: March 1, 2017 Content info: 459 Pages
Description

The full report suite on the U.S. market for orthopedic biomaterials includes bone graft substitutes, which is represented by allografts, demineralized bone matrix, and synthetic bone graft market. The report also includes orthopedic growth factors, cellular allografts, orthopedic cell therapy, hyaluronic acid viscosupplementation, orthopedic cartilage repair, and spinal machined bone allograft markets.

General Report Contents:

  • Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends
  • Market Drivers & Limiters for each chapter segment
  • Competitive Analysis for each chapter segment
  • Section on recent mergers & acquisitions

Orthopedic biomaterials are associated with high research and development (R&D) costs, which have subsequently led to premium pricing to recoup these initial costs. This is the case for competitors in the cellular allograft, cell therapy and growth factor segments of the U.S. orthopedic biomaterials market. In particular, orthopedic growth factors have had relatively high average selling prices (ASP) since their introduction to the market due to the high costs of recombinant growth factor technologies. The high R&D costs associated with the growth factor segment provide entry barriers against potential competitors. Currently there are only two growth factor BMP-2 products in the United States. Since they're both used in different indications, there is a lack of direct competition, allowing companies such as Medtronic to charge a premium for the Spine indication and recover the large initial costs associated with R&D. The commoditized nature in some parts of the market, such as the allograft and DBM segments, which is due to the lack of product differentiation, has limited growth. The market is being driven by more competitors venturing outside their traditional space to tap into the high growth segments where they can charge a premium. These segments may include the cell therapy and cellular allograft segments, both of which have relatively high ASP.

Table of Contents
Product Code: iDATA_USOB17_MP

TABLE OF CONTENTS

TABLE OF CONTENTS

LIST OF FIGURES

LIST OF CHARTS

EXECUTIVE SUMMARY

U.S. ORTHOPEDIC BIOMATERIALS MARKET OVERVIEW

COMPETITIVE ANALYSIS

MARKET TRENDS

MARKET DEVELOPMENTS

PROCEDURE NUMBERS

MARKETS INCLUDED

KEY REPORT UPDATES

VERSION HISTORY

RESEARCH METHODOLOGY

  • 1.1. RESEARCH SCOPE
  • 1.2. IDATA'S 9-STEP METHODOLOGY
    • Step 1: Project Initiation & Team Selection
    • Step 2: Prepare Data Systems and Perform Secondary Research
    • Step 3: Preparation for Interviews & Questionnaire Design
    • Step 4: Performing Primary Research
    • Step 5: Research Analysis: Establishing Baseline Estimates
    • Step 6: Market Forecast and Analysis
    • Step 7: Identify Strategic Opportunities
    • Step 8: Final Review and Market Release
    • Step 9: Customer Feedback and Market Monitoring

DISEASE OVERVIEW

  • 2.1. BASIC ANATOMY
    • 2.1.1. Osteology and Musculoskeletal System
  • 2.2. DISEASE PATHOLOGY AND DISORDERS
    • 2.2.1. General Diagnostic
    • 2.2.2. Osteoporosis
    • 2.2.3. Osteoarthritis
    • 2.2.4. Indication for Bone Graft Procedure
    • 2.2.5. Indication for Cartilage Repair
    • 2.2.6. Degenerative Disc Disease
  • 2.3. PATIENT DEMOGRAPHICS
    • 2.3.1. General Statistics

PROCEDURE NUMBERS

  • 3.1. PROCEDURE DEFINITIONS
  • 3.2. BONE GRAFT PROCEDURE NUMBERS BY TYPE
  • 3.3. BONE GRAFT SUBSTITUTE PROCEDURE NUMBERS
    • 3.3.1. By Material
    • 3.3.2. By Indication
  • 3.4. GROWTH FACTOR BONE GRAFT PROCEDURE NUMBERS
  • 3.5. CELLULAR ALLOGRAFT PROCEDURE NUMBERS
  • 3.6. CELL THERAPY TREATMENT NUMBERS
    • 3.6.1. Platelet-Rich Treatment Numbers by Indication
    • 3.6.2. Bone Marrow Concentrate Treatment Numbers by Indication
  • 3.7. HYALURONIC ACID TREATMENT NUMBERS BY TYPE
  • 3.8. CARTILAGE REPAIR PROCEDURE NUMBERS BY TYPE
  • 3.9. SPINAL MACHINED BONE ALLOGRAFT PROCEDURE NUMBERS BY APPROACH

ABBREVIATIONS

APPENDIX II: COMPANY PRESS RELEASES

LIST OF CHARTS

  • Chart 1-1: Orthopedic Biomaterials Market by Segment, U.S., 2013 - 2023
  • Chart 1-2: Orthopedic Biomaterials Market Overview, U.S., 2016 & 2023
  • Chart 3-1: Bone Graft Procedure Numbers by Type, U.S., 2013 - 2023
  • Chart 3-2: Bone Graft Substitute Procedure Numbers by Material, U.S., 2013 - 2023
  • Chart 3-3: Bone Graft Substitute Procedure Numbers by Indication, U.S., 2013 - 2023
  • Chart 3-4: Growth Factor Bone Graft Procedure Numbers, U.S., 2013 - 2023
  • Chart 3-5: Cellular Allograft Procedure Numbers, U.S., 2013 - 2023
  • Chart 3-6: Cell Therapy Treatment Numbers by Type, U.S., 2013 - 2023
  • Chart 3-7: Platelet-Rich Plasma Treatment Numbers by Indication, U.S., 2013 - 2023
  • Chart 3-8: Bone Marrow Concentrate Treatment Numbers by Indication, U.S., 2013 - 2023
  • Chart 3-9: Hyaluronic Acid Treatment Numbers by Type, U.S., 2013 - 2023
  • Chart 3-10: Cartilage Repair Procedure Numbers by Type, U.S., 2013 - 2023
  • Chart 3-11: Spinal Machined Bone Allograft Procedure Numbers by Approach, U.S., 2013 - 2023

LIST OF FIGURES

  • Figure 1-1: Orthopedic Biomaterials Market Share Ranking by Segment, U.S., 2016 (1 of 2)
  • Figure 1-2: Orthopedic Biomaterials Market Share Ranking by Segment, U.S., 2016 (2 of 2)
  • Figure 1-3: Companies Researched in this Report, U.S., 2016
  • Figure 1-4: Factors Impacting the Orthopedic Biomaterials Market by Segment, U.S. (1 of 2)
  • Figure 1-5: Factors Impacting the Orthopedic Biomaterials Market by Segment, U.S. (2 of 2)
  • Figure 1-6: Recent Events in the Orthopedic Biomaterials Market, U.S., 2013 - 2016
  • Figure 1-7: Orthopedic Biomaterials Markets Covered, U.S., 2016 (1 of 2)
  • Figure 1-8: Orthopedic Biomaterials Markets Covered, U.S., 2016 (2 of 2)
  • Figure 1-9: Orthopedic Biomaterials Markets Covered, U.S., 2016(1 of 3)
  • Figure 3-1: Bone Graft Procedure Numbers by Type, U.S., 2013 - 2023
  • Figure 3-2: Bone Graft Substitute Procedure Numbers by Material, U.S., 2013 - 2023
  • Figure 3-3: Bone Graft Substitute Procedure Numbers by Indication, U.S., 2013 - 2023 (1 of 2)
  • Figure 3-4: Bone Graft Substitute Procedure Numbers by Indication, U.S., 2013 - 2023 (2 of 2)
  • Figure 3-5: Growth Factor Bone Graft Procedure Numbers, U.S., 2013 - 2023
  • Figure 3-6: Cellular Allograft Procedure Numbers, U.S., 2013 - 2023
  • Figure 3-7: Cell Therapy Treatment Numbers by Type, U.S., 2013 - 2023
  • Figure 3-8: Platelet-Rich Plasma Treatment Numbers by Indication, U.S., 2013 - 2023
  • Figure 3-9: Bone Marrow Concentrate Treatment Numbers by Indication, U.S., 2013 - 2023
  • Figure 3-10: Hyaluronic Acid Treatment Numbers by Type, U.S., 2013 - 2023
  • Figure 3-11: Cartilage Repair Procedure Numbers by Type, U.S., 2013 - 2023
  • Figure 3-12: Spinal Machined Bone Allograft Procedure Numbers by Approach, U.S., 2013 - 2023
  • Figure 5-1: Press Release Summary
Back to Top